Mechanistic insights into the effect of midazolam on the malignant progression of ovarian cancer
Cytojournal · 04.11.2025 · 22 · 91
DOI: 10.25259/cytojournal_25_2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytojournal, online erschienen am 04.11.2025. Verfasst von Xiaokun Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology Surgery, Qingdao Traditional Chinese Medicine Hospital, Qingdao Hiser Hospital Affiliated of Qingdao University, Qingdao…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
As the first gynecological tumor, ovarian cancer seriously threatens women’s lives and health. Here, the possible mechanism of midazolam against ovarian cancer progression was investigated. Material and Methods: OVCAR3 and SKOV3 cells were treated with midazolam for 24 h, and cell activity was subsequently detected by cell counting kit-8 assay to screen for the suitable treatment concentrations of midazolam. Cell proliferation was investigated through 5-ethynyl-2’-deoxyuridine staining and cell plate cloning experiments. Apoptosis rate was detected by flow cytometry, and cell invasion and migration ability were examined through transwell test and scratch test. Western blot was adopted to explore the expression changes of apoptotic proteins, cell cycle-related proteins, and extracellular signal-regulated kinase/c-Jun N-terminal kinase (ERK/JNK) pathway-related proteins.
Results
After midazolam intervention, the OVCAR3 and SKOV3 cells showed decreased proliferation, invasion, and migration abilities and accelerated apoptosis rate. Western blot results displayed that midazolam downregulated the phosphorylation levels of ERK, JNK, and P38. Anisomycin reversed the effect of midazolam on the ERK/JNK pathway and cell proliferation, apoptosis, cell cycle, invasion, and migration.
Conclusion
Midazolam can block the development of ovarian cancer, and the relevant mechanism may be realized through the ERK/JNK pathway.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology Surgery, Qingdao Traditional Chinese Medicine Hospital, Qingdao Hiser Hospital Affiliated of Qingdao University, Qingdao, China.
- Department of Blood Transfusion, Qingdao Traditional Chinese Medicine Hospital, Qingdao Hiser Hospital Affiliated of Qingdao University, Qingdao, China.
Zitieren
APA
Sun, X., Yu, H., Fu, B., & Zhang, Y. (2025). Mechanistic insights into the effect of midazolam on the malignant progression of ovarian cancer. Cytojournal, 22, 91. https://doi.org/10.25259/cytojournal_25_2025
Vancouver
Sun X, Yu H, Fu B, Zhang Y. Mechanistic insights into the effect of midazolam on the malignant progression of ovarian cancer. Cytojournal. 2025;22:91. doi:10.25259/cytojournal_25_2025
BibTeX
@article{Sun2025,
author = {Sun, Xiaokun and Yu, Haifang and Fu, Bing and Zhang, Yun},
title = {Mechanistic insights into the effect of midazolam on the malignant progression of ovarian cancer},
journal = {Cytojournal},
year = {2025},
volume = {22},
pages = {91},
doi = {10.25259/cytojournal_25_2025}
}
EUVIMED